Systemic overexpression of the α1B-adrenergic receptor in mice: An animal model of epilepsy

Epilepsia

Volumn 43, Issue 11, 2002, Pages 1324-1329

  Kunieda, Takeharu ^a   Zuscik, Michael J ^a   Boongird, Atthaporn ^a   Perez, Dianne M ^a   Lüders, Hans O ^a   Najm, Imad M ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE   (United States)

Author keywords

1 Adrenergic receptor; Electroencephalography; Epilepsy; Ictal activity; Transgenic mice

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 1B ADRENERGIC RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTROENCEPHALOGRAM; EPILEPSY; EPILEPTOGENESIS; MOUSE; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; STRESS; TRANSGENIC MOUSE;

ANIMALS; ELECTROENCEPHALOGRAPHY; EPILEPSY; MICE; MICE, TRANSGENIC; RECEPTORS, ADRENERGIC, ALPHA-1; VIDEOTAPE RECORDING;

EID: 0036851841     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1528-1157.2002.13202.x     Document Type: Article

References (47)

1. Guarino RD, Perez DM, Piascik MT. Recent advances in the molecular pharmacology of the alpha 1-adrenergic receptors. Cell Signal 1996;8:323-33.
2. Piascik MT, Perez DM. Alpha1-adrenergic receptors: New insights and directions. J Pharmacol Exp Ther 2001;298:403-10.
3. Mouradian RD, Sessler FM, Waterhouse BD. Noradrenergic potentiation of excitatory transmitter action in cerebrocortical slices: Evidence for mediation by an alpha 1 receptor-linked second messenger pathway. Brain Res 1991;546:83-95.
4. McCormick DA, Pape HC, Williamson A. Actions of norepinephrine in the cerebral cortex and thalamus: Implications for function of the central noradrenergic system. Prog Brain Res 1991;88:293-305.
5. Lerea LS, McCarthy KD. Astroglial cells in vitro are heterogeneous with respect to expression of the alpha 1-adrenergic receptor. Glia 1989;2:135-47.
6. Amabeoku G, Chandomba R. Strychnine-induced seizures in mice: The role of noradrenaline. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:753-63.
7. Kirkwood A, Rozas C, Kirkwood J, Perez F, Bear MF. Modulation of long-term synaptic depression in visual cortex by acetylcholine and norepinephrine. J Neurosci 1999;19:1599-609.
8. Beani L, Tanganelli S, Antonelli T, Bianchi C. Noradrenergic modulation of cortical acetylcholine release is both direct and gamma-aminobutyric acid-mediated. J Pharmacol Exp Ther 1986;236:230-6.
9. Zuscik MJ, Sands S, Ross SA, et al. Overexpression of the alpha1B-adrenergic receptor causes apoptotic neurodegeneration: Multiple system atrophy. Nat Med 2000:6:1388-94.
10. Zuscik MJ, Piascik MT, Perez DM. Cloning, cell-type specificity, and regulatory function of the mouse alpha(1B)-adrenergic receptor promoter. Mol Pharmacol 1999;56:1288-97.
11. Hwa J, Gaivin R, Porter JE, Perez DM. Synergism of constitutive activity in alpha 1-adrenergic receptor activation. Biochemistry 1997;36:633-9.
12. Spencer SS, Guimaraes P, Katz A, Kim J, Spencer D. Morphological patterns of seizures recorded intracranially. Epilepsia 1992;33:537-45.
13. Delgado-Escueta AV, Greenberg DA. Mapping genes in juvenile myoclonic epilepsy. Rev Neurol 1987;143:351-62.
14. Ottman R, Risch N, Hauser WA, et al. Localization of a gene for partial epilepsy to chromosome 10q. Nat Genet 1995;10:56-60.
15. Berkovic SF, Howell RA, Hay DA, Hopper JL. Epilepsies in twins: Genetics of the major epilepsy syndromes. Ann Neurol 1998;43: 435-45.
16. Krall RL, Penry JK, White BG, Kupferberg HJ, Swinyard EA. Antiepileptic drug development: II. Anticonvulsant drug screening. Epilepsia 1978;19:409-28.
17. Krall RL, Penry JK, Kupferberg HJ, Swinyard EA. Antiepileptic drug development: I. History and a program for progress. Epilepsia 1978;19:393-408.
18. McNamara JO. Cellular and molecular basis of epilepsy. J Neurosci 1994;14:3413-25.
19. Seyfried TN, Glaser GH. A review of mouse mutants as genetic models of epilepsy. Epilepsia 1985;26:143-50.
20. Kelley KA, Ho L, Winger D, et al. Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2. Am J Pathol 1999;155:995-1004.
21. Morton AJ, Leavens W. Mice transgenic for the human Huntington's disease mutation have reduced sensitivity to kainic acid toxicity. Brain Res Bull 2000;52:51-9.
22. Musumeci SA, Bosco P, Calabrese G, et al. Audiogenic seizures susceptibility in transgenic mice with fragile X syndrome. Epilepsia 2000;41:19-23.
23. Noebels JL. Analysis of inherited epilepsy using single locus mutations in mice. Fed Proc 1979:38:2405-10.
24. Noebels JL, Sidman RL. Inherited epilepsy: Spike-wave and focal motor seizures in the mutant mouse tottering. Science 1979;204:1334-6.
25. Imaisumi K, Ito S, Kutsukake G, Takizawa T. Fujiwara K, Tujikawa K. Epilepsy-like anomaly of mice. Exp Anim 1959;8:6-10.
26. Suzuki J. Paroxysmal discharges in the electroencephalogram of the El mouse. Experientia 1976:32:336-8.
27. Oguro K, Ito M, Tsuda H, et al. NMDA-sensitive L-[3H]glutamate binding in cerebral cortex of El mice. Epilepsy Res 1990;6:211-4.
28. Oguro K, Ito M, Tsuda H, et al. Association of NMDA receptor sites and seizures of El mice. Epilepsy Res 1991;9:225-30.
29. Todorova MT, Burwell TJ, Seyfried TN. Environmental risk factors for multifactorial epilepsy in EL mice. Epilepsia 1999;40:1697-707.
30. Yanai J. Genetic factors in drug neuroteratogenicity. Subst Alcohol Actions Misuse 1983;4:19-30.
31. Tecott LH, Sun LM, Akana SF, et al. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 1995;374:542-6.
32. Corcoran ME, Mason ST. Role of forebrain catecholamines in amygdaloid kindling. Brain Res 1980;190:473-84.
33. Gross RA, Ferrendelli JA. Relationships between norepinephrine and cyclic nucleotides in brain and seizure activity. Neuropharmacology 1982;21:655-61.
34. Mueller AL, Palmer MR, Hoffer BJ, Dunwiddie TV. Hippocampal noradrenergic responses in vivo and in vitro. Characterization of alpha and beta components. Naunyn Schmiedebergs Arch Pharmacol 1982;318:259-66.
35. Kobilka BK, Matsui H, Kobilka TS, et al. Cloning, sequencing, and expression of the gene coding for the human platelet alpha 2-adrenergic receptor. Science 1987;238:650-6.
36. Wilson MH, Puranam RS, Ottman R, et al. Evaluation of the alpha(2A)-adrenergic receptor gene in a heritable form of temporal lobe epilepsy. Neurology 1998;51:1730-1.
37. Pralong E, Magistretti PJ. Noradrenaline reduces synaptic responses in normal and tottering mouse entorhinal cortex via alpha 2 receptors. Neurosci Lett 1994;179:145-8.
38. Pralong E, Magistretti PJ. Noradrenaline increases K-conductance and reduces glutamatergic transmission in the mouse entorhinal cortex by activation of alpha 2-adrenoreceptors. Eur J Neurosci 1995;7:2370-8.
39. Westerberg V, Lewis J, Corcoran ME. Depletion of noradrenaline fails to affect kindled seizures. Exp Neurol 1984;84:237-40.
40. Horton R, Anlezark G, Meldrum B. Noradrenergic influences on sound-induced seizures. J Pharmacol Exp Ther 1980;214:437-42.
41. Janumpalli S, Butler LS, MacMillan LB, Limbird LE, McNamara JO. A point mutation (D79N) of the alpha2A adrenergic receptor abolishes the antiepileptogenic action of endogenous norepinephrine. J Neurosci 1998;18:2004-8.
42. Fletcher A, Forster EA. A proconvulsant action of selective alpha 2-adrenoceptor antagonists. Eur J Pharmacol 1988;151:27-34.
43. Dunn RW, Corbett R. Yohimbine-induced seizures involve NMDA and GABAergic transmission. Neuropharmacology 1992;31:389-95.
44. De Sarro G, Ongini E, Bertorelli R, Aguglia U, De Sarro A. Excitatory amino acid neurotransmission through both NMDA and non-NMDA receptors is involved in the anticonvulsant activity of felbamate in DBA/2 mice. Eur J Pharmacol 1994;262:11-9.
45. Pericic D, Jazvinscak M, Svob D, Mirkovic K. Beta-1 adrenoceptor antagonists potentiate the anticonvulsive effect of swim stress in mice. Pharmacol Biochem Behav 2000;67:507-10.
46. Ivanov A, Aston-Jones G. Extranuclear dendrites of locus coeruleus neurons: Activation by glutamate and modulation of activity by alpha adrenoceptors. J Neurophysiol 1995;74:2427-36.
47. Bakshi VP, Geyer MA. Alpha-1-adrenergic receptors mediate sensorimotor gating deficits produced by intracerebral dizocilpine administration in rats. Neuroscience 1999;92:113-21.